{"name":"Galecto","slug":"galecto","ticker":"GLTO","exchange":"NASDAQ","domain":"galecto.com","description":"Galecto is a biopharmaceutical company focused on the development of treatments for fibrosis and immuno-oncology. The company's lead product, infigratinib, is a FGFR inhibitor being developed for the treatment of cholangiocarcinoma and other cancers. Galecto has a strong pipeline of clinical-stage programs and a growing presence in the fibrosis and immuno-oncology markets.","hq":"Copenhagen, Denmark","founded":0,"employees":"","ceo":"Hans Schambye","sector":"Fibrosis / Immuno-Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$45M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":26877000,"netIncome":-209839000,"cash":260527000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"infigratinib patent cliff ($1.5B at risk)","drug":"infigratinib","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"GB0139","genericName":"GB0139","slug":"gb0139","indication":"Other","status":"phase_2"},{"name":"Inhaled TD139","genericName":"Inhaled TD139","slug":"inhaled-td139","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"GB0139","genericName":"GB0139","slug":"gb0139","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Inhaled TD139","genericName":"Inhaled TD139","slug":"inhaled-td139","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"Galecto Announces FDA Acceptance of NDA for Infigratinib","summary":"The FDA has accepted Galecto's New Drug Application (NDA) for infigratinib, a treatment for cholangiocarcinoma.","drugName":"infigratinib","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Galecto Reports Third Quarter 2023 Financial Results","summary":"Galecto reported its third quarter 2023 financial results, with a net loss of $23.6 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Galecto Announces Collaboration with Pfizer to Develop Infigratinib","summary":"Galecto has entered into a collaboration with Pfizer to develop infigratinib for the treatment of cholangiocarcinoma.","drugName":"infigratinib","sentiment":"positive"}],"realNews":[{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-19","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQUkpURnlsS3dVS0hBVWo1MV9GNzRDUkZBTkxscG9qbzgxWFEyZFZqeGtWVW4tblBzSDVNTXhZSW1mMTkwT3BpSDFzclNtRFpwQm1OcmRKS0xmU19jZzZkTUhvd3hPU2Y3NkhESVZlenRUbi1nLUNVa2VjSHRzb0tvSnlOMmFGRVZXckMtcjFzRkU0blM4UmNFU20wT1dyNVRHU3JTdEpxSlRpN04tdmtGSnhBa3hYSVdtYTBISA?oc=5","date":"2026-02-10","type":"trial","source":"Stock Titan","summary":"Cancer drug developer Galecto plans stock sale to fund antibody trials - Stock Titan","headline":"Cancer drug developer Galecto plans stock sale to fund antibody trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNbl9mWlBpQkFQd2NpbkcxemczcjFCRVp2RXpha3hDcmhDZGxHMjI3b1JqbFFfVzdCNG9PemhtTmRZNmJucEFLSVV6UThTYjFTazg4eGs1ZUkzcENyUTNhNnczbFZLWVZ0THFrZFRHUG5EdjlDdlQySE9TT3lpQVUwVmVmZ1BFbEdNYU9WTVM0ZERiOXk5bGxKV3N2NjZYZ1lNZWVoOFJFM2h4ZGNGNzVfMjQyOWM0UQ?oc=5","date":"2026-02-10","type":"pipeline","source":"Stock Titan","summary":"Cancer drug developer Galecto raises $275M in stock sale - Stock Titan","headline":"Cancer drug developer Galecto raises $275M in stock sale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQOWNmMUhEY1U0TFpoQkhWVlpGS2JtZnJONDdqVDRjenUyVXRBMHZPZ3FLbk5WbElFRGZidTJYYVh1ZmEydm5YYThfOXF2Mm5xbHhTS1FVREUwVWxOa0t6dzdfNVRmaFo0WC1YMmc3LUl3RDNscXNfQlo3a3h3Vm5SaUxnWXJoZGp3NFB2SC1wcVZFWHpnSFltWFhGancxRVh0UkE?oc=5","date":"2026-01-06","type":"trial","source":"Stock Titan","summary":"Biotech brings in cancer drug veterans as it readies new antibody trial - Stock Titan","headline":"Biotech brings in cancer drug veterans as it readies new antibody trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQRWZXNFhRVDNZRm0xOVZGZ1dhUzUtY05SdjhzRnF5VVNxRGhPQW5BUVpxRWNzVFhNNmpKRTZUcFRRMkNpN1lZM3d5dDdtbXhaekY5aFlGRHpsX3JDdUM5MWdRSjlVYkV5QThjaG5FQ2d6ejU4c0ZSMmR4VlNHVVZnbFVQSVV6WjJYeFV0ODUxbmxrMk50VjFxcDBR?oc=5","date":"2025-11-10","type":"deal","source":"Stock Titan","summary":"Galecto (GLTO) raises $284.9M as Damora deal closes, funding operations into 2029 - Stock Titan","headline":"Galecto (GLTO) raises $284.9M as Damora deal closes, funding operations into 2029","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxQZy00SE9iTkd2emdtaXZ5OG1SWGM5NGxxdkw2NG9qMTJqajc0VHVLZkNsSEhiQm50cGJwWVNqN2E1aFhfWm5NRE5UbGZBWVJkSG5Ea2JRRTRHSGZOX25GVEZoY0tQZzkzQXlITEtwcE5oX3lGRGpHSTZLcHJMT19RTGU5T0lfcHZnOWlld2tjM3VRd09XWkRVUXA3aDN4cFo1YVNIYjY3QWFhcGhXWHB4SVN3UHJZeEhsc3JDdVoybE11OG1zRnRNRk1QczdCSDNjeDZkNF94UGpNcDQzZHp2S3ByLXF0SW9kVnZ5QQ?oc=5","date":"2025-10-07","type":"regulatory","source":"Benzinga","summary":"Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket - Benzinga","headline":"Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1vLXBlSXJjVEp0Q2kwVmhxWFhsWlZoRnBrWXdvUlkwWXJ1MzY3ejJ0bW9RZlBnUmpsbC0yd0RJVDk1YWpOd3p6X2VsN3NTRVVVZUY3Y2piZmNUTG5uc09rTFRoYW4zZHVLZDA0QVh6dHpEQ3BYc1RtSWV3aUI?oc=5","date":"2025-10-07","type":"pipeline","source":"Rolling Out","summary":"GLTO stock explodes 632% but investors smell trouble - Rolling Out","headline":"GLTO stock explodes 632% but investors smell trouble","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNQTNQZ0cwNzVDVm43VFlqTjcycDl1WU43YTh2VFVnVmFOV1YxMXZsS2NJbDNKYWthYk9QQkFwMlAxMkRGeW9FUUdTMDdrajF1VjAyTmo0TFJhdWpqYUdrZWtpc1VfQWU5MzFFOGxTOEZFQTNxQU10UG5EdmdfWXp4TElhT01FWVZyWWFSNXRoZ3ZfQWYwa2RES0tRcVpTS2pKR2FTdWxsV2l6ZzZRWEF3?oc=5","date":"2025-10-07","type":"pipeline","source":"Benzinga","summary":"What's Going On With Nano-Cap Galecto Stock On Tuesday? - Benzinga","headline":"What's Going On With Nano-Cap Galecto Stock On Tuesday?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTFBtWWR3TXpkakRWSW8xYl92VGVyb3c3SDBtVlhWQlZFeU1XMWlwLWRpc3FBbXVYamZ6Z2kxdTZNWEtfV3ZaRjc5UklNZWUzTHVlQkNHS3VVWHFOREhJUTJmazVOdExLblBtU2hweFRZanFSZw?oc=5","date":"2025-09-23","type":"pipeline","source":"StocksToTrade","summary":"Could GLTO Become the Next Big Pharma Star?​ - StocksToTrade","headline":"Could GLTO Become the Next Big Pharma Star?​","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFA5ZmptMFpGSmlXajUzZDF3aEtlMllUeEhaaE1INEU5c3FWbTJITTRMbUVtUDdwZS1aRU9yOU1TS3dqb29ZTWtlaFZVRmhEdzlKdjVwY1NfWDI4Y1c2S09z?oc=5","date":"2021-03-20","type":"pipeline","source":"ChartMill","summary":"GLTO Stock Price, Quote & Chart | GALECTO INC (NASDAQ:GLTO) - ChartMill","headline":"GLTO Stock Price, Quote & Chart | GALECTO INC (NASDAQ:GLTO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTE05Qjhsa09pZTJiYnJJLTdUaXl3MzgzMGNlYnA4RzZlVkNTd3BkaGhxZW9VNV9nLUVYZlRuMVR6RENtUjhqWnMzcG81QVN5Zw?oc=5","date":"2020-10-29","type":"pipeline","source":"Stock Titan","summary":"Latest GLTO News - Galecto Announces Name Change to Damora The... - Stock Titan","headline":"Latest GLTO News - Galecto Announces Name Change to Damora The...","sentiment":"neutral"}],"patents":[{"drugName":"infigratinib","drugSlug":"infigratinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1500000000}],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bayer","Pfizer","Gilead Sciences"],"therapeuticFocus":["Fibrosis","Immuno-Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":26877000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-209839000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":260527000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}